{"id":"W2994649246","doi":"10.1200/jco.2012.30.15_suppl.6512","title":"BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Bosutinib; Cumulative incidence; Imatinib; Adverse effect; Gastroenterology; Myeloid leukemia; Imatinib mesylate; Cohort; Dasatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00308642,0.0006195744,0.001739656,0.0003888408,0.000258889,0.00123756,0.0008869392,0.001184639,0.007597639],"category_scores_gemma":[0.002588989,0.0003106973,0.001244527,0.0004905709,0.0002244532,0.0006900665,0.000518018,0.002140017,0.001514344],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007206774,"about_ca_system_score_gemma":0.001051408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001089595,"about_ca_topic_score_gemma":0.004734328,"domain_scores_codex":[0.9993104,0.0003949413,0.00005609932,0.00005567146,0.0001253442,0.00005756139],"domain_scores_gemma":[0.9981095,0.0006549501,0.0005867883,0.00005026722,0.0001884055,0.0004101516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3384394,0.003083154,0.01142775,0.01150268,0.005796029,0.000347768,0.0002305146,0.002384025,0.009348396,0.002354289,0.2374269,0.3776591],"study_design_scores_gemma":[0.5948852,0.06005976,0.07576966,0.003705148,0.01055315,0.00123487,0.0001895211,0.003572084,0.001444846,0.002190729,0.2462637,0.0001313771],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4846288,0.3300815,0.003839429,0.03665115,0.007392982,0.004887661,0.07288169,0.00159167,0.05804515],"genre_scores_gemma":[0.6882253,0.1138007,0.0109316,0.03628898,0.007606097,0.01159294,0.09528194,0.0003654717,0.03590691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007597639,"threshold_uncertainty_score":0.02541661,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05549353463803525,"score_gpt":0.4012374452953767,"score_spread":0.3457439106573415,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}